Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine
A Randomised, Double-blind, Parallel Group, Roll-over Study Evaluating Long-term Safety and Efficacy of Oral Doses of BI 1291583 q.d. in Patients With Bronchiectasis (Clairleafᵀᴹ)
Sponsor: Boehringer Ingelheim
A PHASE2 clinical study on Bronchiectasis, this trial is ongoing. The trial is conducted by Boehringer Ingelheim and has accumulated 27 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
27 versions recorded-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE2
-
Feb 2026 — Mar 2026 [monthly]
Active Not Recruiting PHASE2
-
Nov 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE2
-
Sep 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE2
-
May 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
▶ Show 22 earlier versions
-
Apr 2025 — May 2025 [monthly]
Active Not Recruiting PHASE2
-
Mar 2025 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
-
Jan 2025 — Mar 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Dec 2024 — Jan 2025 [monthly]
Recruiting PHASE2
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE2
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE2
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE2
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE2
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE2
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2023 — Aug 2023 [monthly]
Not Yet Recruiting PHASE2
-
Jun 2023 — Jul 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalborg, Denmark , Aichi, Nagoya, Japan , Amiens, France , Amsterdam, Netherlands , Aomori, Hirosaki, Japan , Barcelona, Spain , Beersheba, Israel , Berlin, Germany , Bialystok, Poland , Budapest, Hungary and 85 more locations